New data suggests HIV superinfection rate comparable to initial HIV infection

June 7, 2012

HIV superinfection, when a person with HIV could acquire a second, new strain of HIV, may occur as often as initial HIV infection in the general population in Uganda, a study suggests.

Since researchers demonstrated more than a decade ago that a person infected with HIV could subsequently acquire a second, new strain of HIV, there has been little agreement in the scientific community as to how often HIV superinfection occurs. Previous studies have found HIV superinfection to be relatively frequent among individuals who engaged in high-risk behaviors, but the rate of superinfection in general populations remained unclear. The new study, supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, offers some evidence about the likelihood.

In light of the study's findings, the authors say post-test counseling for individuals newly diagnosed with HIV infection should emphasize the risk of HIV superinfection and the possible health implications of continuing practices that put them at risk for HIV. Studies of the rate of new cases, or annual incidence rates, of HIV superinfection, including those conducted in the United States, estimate 4 percent incidence among highly sexually active people diagnosed with HIV infection.

"This study indicates that HIV superinfection may be more common than was previously thought," said NIAID Director Anthony S. Fauci, M.D. "These findings have implications for public health strategies to prevent new infections and efforts to develop an HIV vaccine. In addition, they are important because HIV superinfection can accelerate disease progression and the development of drug resistance, even in individuals who were previously controlling their HIV infection."

The study, published online in the Journal of Infectious Diseases, was led by Thomas C. Quinn, M.D., and Andrew D. Redd, Ph.D., of NIAID's Laboratory of Immunoregulation, and Maria J. Wawer, M.D., Ph.D., formerly of the Johns Hopkins University Bloomberg School of Public Health, Baltimore, and now with Columbia University Mailman School of Public Health, New York City. Their collaborators included researchers at NIAID's Rocky Mountain Laboratories, Hamilton, Mont., the Rakai Health Sciences Program in Kalisizo, Uganda, and Makerere University in Kampala, Uganda.

The blood samples examined in the study were from the ongoing NIH-supported Rakai Community Cohort Study (RCCS), a community-based open study of heterosexual men and women ages 15 to 49 years old in rural Rakai District, Uganda. Since 1994, researchers working with the RCCS have been annually conducting interviews and collecting blood samples from approximately 14,000 consenting individuals in 50 Ugandan villages to better understand HIV infection and its risk factors and to develop potential preventive measures.

"Previous studies of HIV superinfection have focused on individuals exposed to the virus through high-risk sexual activity or intravenous drug use," said lead author Dr. Redd. "We wanted to determine the rate of HIV superinfection among a broader, general population using a novel technique sensitive enough to detect even the lowest levels of circulating HIV strains."

Using an advanced high-throughput genetic screening method called next-generation ultra-deep sequencing, the scientists examined blood samples from RCCS participants who became HIV infected. The screening was designed to detect differences in the distinctly positioned and relatively restricted p24 and gp41 genes of the virus and could detect a virus that represented as little as 1 percent of the total viruses circulating in the blood if it were of a different HIV subtype, or genetically related subgroup.

The researchers tested two blood samples. The first samples were taken at initial HIV diagnosis between 1998 and 2004, and the second samples were taken at least a year later, before the infected individuals began antiretroviral therapy. The samples were analyzed to find examples where the initial infecting strain did not cluster with viral strains found at a later time, thus confirming HIV superinfection. The rate of superinfection was then compared with an estimated overall HIV incidence rate for the entire population of initially HIV-negative individuals during the same time period.

Of the samples tested from 149 HIV-infected people, the scientists found seven cases of HIV superinfection, all detected in the gp41 region of the virus. Of these cases, four individuals were initially infected and then later superinfected with different strains of HIV subtype D, the most common viral subtype found in Rakai. The other three were initially infected with subtype D and superinfected with a different HIV subtype, subtype A. These findings suggest a rate of superinfection of 1.44 per 100 people annually. The investigators were surprised to find that the rate of superinfection was comparable to the current estimated annual rate of new, initial HIV infections in the Rakai cohort, or 1.15 infections per 100 people per year. HIV superinfection had been thought to be less common than initial infection.

"Our findings suggest that HIV vaccine strategies designed to recreate the natural immune response to HIV may be insufficient to protect an individual from infection," Dr. Redd noted. "However, the data also provide an interesting new population to explore since it is possible that some individuals will be protected from superinfection. Determining what controls superinfection could lead to new avenues for vaccine research."

Explore further: HIV 'superinfection' boosts immune response

More information: "The Rates of HIV Superinfection and Primary HIV Incidence in a General Population in Rakai, Uganda," was written by Andrew D. Redd, Caroline E. Mullis, David Serwadda, Xiangrong Kong, Craig Martens, Stacy M. Ricklefs, Aaron A. R. Tobian, Changchang Xiao, Mary K. Grabowski, Fred Nalugoda, Godfrey Kigozi, Oliver Laeyendecker, Joseph Kagaayi, Nelson Sewankambo, Ronald H. Gray, Stephen F. Porcella, Maria J. Wawer and Thomas C. Quinn.

Related Stories

HIV 'superinfection' boosts immune response

March 29, 2012
Women who have been infected by two different strains of HIV from two different sexual partners – a condition known as HIV superinfection – have more potent antibody responses that block the replication of the virus ...

Researchers discuss challenges to developing broadly protective HIV vaccines

September 7, 2011
The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not ...

Adaptive trial designs could accelerate HIV vaccine development

April 20, 2011
In the past 12 years, four large-scale efficacy trials of HIV vaccines have been conducted in various populations. Results from the most recent trial—the RV144 trial in Thailand, which found a 31 percent reduction ...

Recommended for you

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.